Overview

• Biotechnology firm's Q4 revenue fell significantly yr/yr

• Net loss for Q4 increased compared to the previous year

• Company expects 2026 net cash used in operations to decrease

Outlook

• Prothena expects 2026 net cash used in operations to be $50 to $55 mln

• Company anticipates ending 2026 with approximately $255 mln in cash

Result Drivers

• REVENUE DECLINE - Q4 revenue decreased significantly due to lower collaboration revenue from Bristol Myers Squibb

• R&D EXPENSES - Decrease in R&D expenses due to lower clinical trial, personnel, manufacturing, and consulting costs

• RESTRUCTURING IMPACT - Net loss includes restructuring charges and valuation allowance against deferred tax assets

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Prothena Corporation PLC is $18.50, about 103.5% above its February 18 closing price of $9.09

Press Release: ID:nBw5pV9mFa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)